Macrophages were shown by the use of glomerular cell culture and morphologic techniques to be present in large numbers within the glomeruli of rabbits with acute serum sickness (AcSS) and in a passive model of the autologous phase of antiglomerular basement membrane (GBM) antibody-induced glomerulonephritis (PAGBMN). To determine the part played by these cells in the glomerular injury, animals were treated with a sheep anti-rabbit macrophage serum (AMS) or normal sheep serum (NSS). NSS administration had no effect on the development of either model of glomerulonephritis. The use of AMS reduced the number of circulating monocytes and prevented the accumulation of macrophages within glomeruli in both models (AcSS/NSS, mean 126/glomerulus, range 40-251; AcSS/AMS, mean 8, range 1-44; PAGBMN/NSS, mean 52, range 27-69; PAGBMN/AMS, mean 5, range 2-7). The AMS-treated rabbits had only minor histologic lesion and profound reduction in proteinuria (AcSS/NSS, mean 516 mg/24 h, range 200-991; AcSS/AMS, mean 41, range 3-161; PAGBMN/NSS, mean 335, range 55-975; PAGBMN/AMS, mean 10, range 2-24). Similar studies in the heterologous phase of glomerular injury induced by the same anti-GBM antibody revealed no effect of the AMS on this polymorphonuclear leukocyte-related phase of injury, demonstrating the selectivity of the antisera. Complement depletion, with cobra venom factor, did not affect the development of glomerulonephritis nor the accumulation of macrophages in either model. Inhibition of macrophage […] Find the latest version: Similar studies in the heterologous phase of glomerular injury induced by the same anti-GBM antibody revealed no effect of the AMS on this polymorpho-
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INTRODUCTION
Several mediators of inflammation, including the polymorphonuclear leukocyte (PMN)' (1, 2) the complement (1, 3) , and the coagulation system (4, 5) , are capable ofproducing glomerular injury in experimental immunologic glomerulonephritis. The ability of these mediators to promote glomerular injury has been defined in large part by observing the effects of their selective depletion before or during the development of the experimental lesion (1) (2) (3) (4) (5) (6) . Additional systems remain to be defined because some experimental immunologic glomerulonephritis, for example, acute serum sickness (AcSS) (3, 6) and certain forms of antiglomerular basement membrane (GBM) antibodyinduced disease, occur in the absence of complement and PMN (7) . Recently, macrophages have been identified in immunologically initiated glomerular injury such as acute (8, 9) and chronic (10) proliferative glomerulonephritis in man, and in experimental animal models including anti-GBM antibody-induced disease in rabbits (11) and rats (12, 13) , "autoimmune" glomerulonephritis in sheep (11) , immune complex-mediated glomerulonephritis, e.g., acute (14, 15) and chronic (15) serum sickness in rabbits, as well as passive serum sickness in mice (16, 17) . Beyond its presence, the functional importance of the macrophage has not been extensively explored. Depletion of inflammatory cells by irradiation suggests that monocytes play a role in an augmented autologous phase of anti-GBM antibodyinduced glomerulonephritis in rats (12) . Also, the use of an antilymphocyte serum with activity against lymphocytes and esterase-positive cells substantially decreased 24 h proteinuria and the glomerular ingress of mononuclear cells appearing within 30 min of the injection of heterologous anti-GBM antibody to rats (18) .
Our recent findings of a close temporal relationship between macrophage accumulation and extent of glomerular damage in acute (and chronic) serum sickness suggests that macrophages play a significant role in these models of experimental immune complex glomerulonephritis (15) . To establish the role of macrophage infiltration in glomeruli as a major mediator of glomerular damage, independent of the PMN, an antimacrophage serum (AMS) was used to block macrophage accumulation in glomeruli. Previously, AMS has been used by others to examine the function of macrophages in vivo (19) (20) (21) (22) . The model was examined at five time points in groups of four rabbits: killed 2 h after horse anti-rabbit GBM antibody, injection immediately before the administration of rabbit anti-horse gamma globulin antibody, and 2, 12, and 24 h later. The horse anti-rabbit GBM antibody was prepared by repeated immunization with particulate rabbit renal basement membrane in complete Freund's adjuvant. The antiserum was decomplemented (56°C for 30 min) and absorbed with rabbit serum and erythrocytes. Normal horse gamma globulin was used as immunogen to produce the rabbit anti-horse gamma globulin antibody in rabbits. (25) , and CHO (6) Heterologous phase anti-GBM antibody-induced glomerular injury. To evaluate the effect of the AMS on a predominantly PMN-dependent model of experimental glomerulonephritis, rabbits were given intravenously 40 ,Ag/g of horse kidney anti-rabbit GBM antibody. Six rabbits received nitrogen mustard as described above, six received AMS (200 mg 2 h before and 10 h after the horse anti-rabbit GBM antibody), and six were untreated. Proteinuria (24) was measured over the subsequent 24 h, the rabbits killed, and morphologic damage and number of macrophages per glomerulus determined. Eight additional rabbits (four treated with 200 mg AMS i.p.) received the same dose of horse antirabbit GBM antibody and were examined 2 h later to assess the accumulation of PMN. Glomerular cell culture to quantitate glomerular macrophages. Glomeruli were cultured and the number of macrophages present in the outgrowths of individual glomeruli determined (11, 15, 28, 29 Assessment in vitro. The effects of AMS on macrophages harvested from rabbit's peritoneum, as described above, and PMN obtained from the peritoneum of other rabbits 4 h after the i.p. injection of glycogen (50 ml/kg, 0.1%, J. T. Baker Chemical Co., Phillipsburg, N. J.) were assessed. Spleen cells were teased from fresh normal rabbit spleens and passed through glass wool to remove adherent cells. Mononuclear cells were purified from heparinized blood by sedimentation through 6% dextran T500 (Pharmacia, Uppsala, Sweden) for 30 min at 37°C, and centrifugation through FicollHypaque at 400 g for 30 The effect of the AMS or NSS (1 or 3%) on phagocytosis of latex particles (1.1 ,um, Sigma Chemical Co., St. Louis, Mo.) was studied using aliquots of blood monocytes and PMN. After incubation at room temperature for 10 min, latex particles were added to the cells and gently mixed for 20 min.
Washed cells were smeared on glass slides and stained with Wright's stain, and the number of latex particles taken up per cell was determined under oil immersion microscopy with 10 replicate counts per smear averaged.
The viability of cells treated with AMS or NSS was determined with fluorescein diacetate (30) (Sigma Chemical Co.). Dilutions of AMS or NSS (1, 3, or 10%) were added to 1.2 x 106 peritoneal macrophages in 500 1l MEM-1% FCS for 30 min at room temperature. 2 ,ul of fluorescein diacetate (5 mg/ml) was added and incubated for 15 min at room temperature, after which the cells were washed and examined by fluorescence microscopy. The means of five replicate counts on each of two slides were obtained in two different experiments. Viable cells hydrolyze fluorescein diacetate releasing fluorescein which, being polar, is unable to diffuse rapidly from live cells.
Assessment In vivo. Six normal rabbits were injected with 200 mg i.p. of AMS every 12 h for 3 d. Blood was drawn for total and differential leukocyte counts before the initial injection and then 2, 4, and 12 h later. Counts were repeated 2 and 12 h after each subsequent dose. Hematocrits and platelet counts were also determined 4 h after each dose. Six control rabbits were injected intraperitoneally with an equal quantity of NSS and similar measurements made. Urine was collected over each 24 h period for the quantitation of proteinuria; the rabbits in both groups were killed after 3 d and histologic assessment made of the kidneys, spleen, liver, heart, and lung. (31) . AMS was fluoresceinated as previously described (31) .
RESULTS
Characterization of the PAGBMN model. The subnephritogenic dose of horse anti-rabbit GBM antibody did not induce proteinuria (mean 6 mg/15 h; range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] or glomerular injury. After rabbit anti-horse gamma globulin antibody administration proteinuria regularly occurred (mean 299 mgld; range 40-1,036) (Table I) . Only occasional PMN were observed at all time points assessed throughout the evolution of PAGBMN (Table I ). 12 h after the administration of rabbit anti-horse gamma globulin antibody, macrophages were detected in culture, proteinuria was found, and histologic lesions were evident. 24 h after administration of rabbit anti-horse gamma globulin antibody, PAGBMN was characterized by a severe diffuse endocapillary glomerulonephritis in- Effect of cobra venom factor on PAGBMN. Cobra venom factor induced marked and persistent depletion of CH50 and serum C3 levels to < 10% of that measured before PAGBMN induction. Immunofluorescence staining of the glomeruli was negative for C3, whereas staining for horse IgG and rabbit IgG was similar in distribution and extent to that in rabbits without complement depletion. Complement depletion afforded no protection from the induction of injury as seen by light and electron microscopy. The numbers of macrophages per glomerulus (mean 63 macrophages per glomerulus; range 32-106) (Table II) were similar to those detected in glomeruli from untreated controls. Complement depletion did not prevent the development of proteinuria (mean 509 mg/24 h; range 200-1,040) ( Table II) . The neutrophilia known to be induced by cobra venom factor (23) was observed in these rabbits. (Table IV) . Monocyte levels were transiently reduced after administration of NSS (mean 34%) but returned to the normal range by 4 h. AMS, however, produced a marked acute reduction in the monocyte count (mean 91%), which was sustained, so that even at 12 h a mean reduction of 62% was still observed. Similar (Table II) and had morphologic changes indistinguishable from untreated PAGBMN rabbits ( Fig. 2A ).
Rabbits treated with AMS all showed a pronounced amelioration of the histologic lesion and in many cases the glomeruli appeared nearly normal at the light microscopic level (Fig. 2B) . By electron microscopy, the AMS-treated rabbits had residual minor endothelial cell cytoplasmic changes. These consisted of occasional areas of separation from the GBM and some evidence of cytoplasmic swelling (Fig. 1D) . Mononuclear cells were only rarely evident within the lumena, or marginated, and the glomeruli were usually normocellular. There were no differences observed in the immunofluorescence staining pattern for horse IgG, rabbit IgG, and rabbit C3 in the glomeruli from animals with PAGBMN or PAGBMN treated with NSS or AMS.
Very few macrophages were found in the outgrowths of cultured glomeruli from AMS-treated rabbits (mean 5 macrophages per glomerulus; range 2-7) (Table II) .
Glomeruli from NSS-treated rabbits showed a mean of 52 macrophages per glomerulus; (range 27-69) (Table II) (26) , and this was similar for the three groups of rabbits that were randomly allocated to treatment with either AMS (mean 10.5 d; range 9-12) or NSS (mean 9.8 d; range [9] [10] [11] or to no treatment (mean 10.3 d; range 9-12) ( Table V) . The levels of BSA-anti-BSA circulating immune complexes measured daily for the 3 d before immune elimination were also similar (Fig. 3) . The granular deposition of immune reactants (BSA, rabbit IgG, and C3) in the glomeruli was indistinguishable in the three groups. The timing of maximum proteinuria was also the same in each group (Table III) 2 The glomerular histology oftreated PAGBMN and AcSS (A) A PAGBMN rabbit treated with NSS; the lesion was not affected (x320). (B) A PAGBMN rabbit treated with AMS; glomerular injury was profoundly reduced (x320). (C) An AcSS rabbit treated with NSS; there was no effect on the endocapillary lesion (x320). (D) An AcSS rabbit treated with AMS; glomerular structure and cellularity was almost normal (x320).
developed a severe endocapillary glomerulonephritis (Fig. 2C) . However, all the AMS-treated rabbits showed a very marked reduction in the glomerular injury observed at the light microscopic level (Fig. 2D) , although one developed a mild endocapillary lesion. The glomerular ultrastructure of NSS-treated and untreated rabbits was similar. Pronounced intracapillary mononuclear cell accumulation and endothelial cell cytoplasmic prominence formed the basis of the lesion (Fig. 4A) . There was also a mild increase in the mesangia. Epithelial foot process spreading was a common finding. Infrequent electron dense deposits were observed on both sides of the basement membrane as previously reported (15) . Rabbits treated with AMS had a pattern of subendothelial and subepithelial electron dense deposits similar to untreated controls but glomerular hypercellularity was considerably reduced (Fig. 4B) . Some (Table V) . The number of macrophages detected in glomerular outgrowths from AMS-treated rabbits was markedly reduced (mean 8 macrophages per glomerulus; range . The rabbit with the mild glomerular lesion had 44 macrophages per glomerulus. The remaining AMS-treated rabbits had <13 macrophages per glomerulus.
Effect of cobra venom factor on AcSS. In the seven AcSS animals given cobra venom factor, the levels of C3 were reduced by >90% for at least 3 d before immune elimination. The pattern and extent of BSA and IgG deposition was similar to that of untreated rabbits; however, glomerular C3 deposition was prevented. The glomerular histologic and ultrastructural appearance in the six cobra venom factortreated rabbits that eliminated the administered BSA between 9 and 12 d was similar to that in the NSStreated and untreated AcSS groups. The levels of circulating immune complexes were comparable to those measured in AMS-and NSS-treated rabbits (Fig. 3) . The timing of maximum proteinuria (mean day 9.5; range 8-11) and extent of the proteinuria (mean 481 mg/24 h; range 223-783) was similar to that observed in both the untreated and NSS-treated groups (Table V) . The cobra venom factor-treated rabbits had a mean of 89 macrophages per glomerulus (range 41- The inset shows subepithelial electron dense deposits seen in an AMS-treated rabbit (x35,000).
Macrophage-dependent Glomerulonephritis PMN (1, 2), complement (1, 3) , fibrin (4), and platelets (5, 33) in immune glomerular injury has relied heavily on selective mediator depletion. Individually, the mediators contribute to variable degrees in different types of experimental nephritis. Thus complement depletion prevents some forms ofheterologous anti-GBM disease (1), but during AcSS (3) and the autologous phase of anti-GBM disease (34) this maneuver affords no protection. PMN depletion produces considerable protection in some heterologous (1) and autologous (2) phases of anti-GBM disease, although PMN depletion in AcSS (6) has no effect on the glomerular lesions. In many forms of severe (or chronic) experimental glomerulonephritis, several injurious mediators are brought into play simultaneously so that blocking of any one may be insufficient to abrogate completely the inflammatory damage.
To define the potential for macrophages to contribute to glomerular injury, three models were chosen for study. Large numbers of macrophages have been detected by glomerular cell culture during the autologous phase of anti-GBM antibody-induced injury (11, 29) . A passive model of autologous anti-GBM injury was used because it is predictable, homogeneous, and rapid in onset, eliminating the variable of the recipient's autologous antibody response to the planted heterologous antibody. PMN were present in only small numbers in the passive model, whereas they are known to be more prominent in the active autologous phase of anti-GBM antibody injury (2) . This may be due to greater production and deposition of autologous antibody in the active model. Although PMN were not prominent, the PAGBMN model was shown to be dependent on circulating inflammatory cells by depletion of circulating leukocytes with nitrogen mustard administration. To further exclude any effect of the AMS on PMN participation, the heterologous phase of injury induced by the same heterologous anti-GBM antibody was studied without demonstrable effect. The third experimental model chosen was AcSS, in which macrophages are present in large numbers (15) and PMN and complement participation has been excluded by depletion studies (3, 6) . The AMS used in our studies inhibited all macrophage functions tested in vitro; adherence, spreading, and phagocytosis. It rendered the cells metabolically inactive as assessed by viability testing and caused aggregation. In vivo AMS reduced the levels of circulating monocytes without specifically reducing the levels of other leukocytes. The levels of other known inflammatory systems including complement and platelets were not reduced by AMS. The AMS neither specifically influenced the number and function of PMN nor affected the acute heterologous phase of anti-GBM nephritis, a predominantly PMN-mediated glomerular injury. The diminution in glomerular macrophages was associated with a profound reduction in glomerular injury, evidenced by both histologic and electron microscopic study as well as by the functional parameter of urinary protein excretion. Since the AMS caused no detectable change in the underlying immunologic mechanism by influencing binding of anti-GBM antibody or deposition of circulating immune complexes, the beneficial effect ofthe antibody must be attributed to its ability to reduce macrophage accumulation within glomeruli. The exact mode of action of the AMS in preventing glomerular accumulation of macrophages was not studied, but presumably includes actions such as inhibition of adherence and spreading as noted in vitro, since complete removal of circulating monocytes was not achieved although depressions of 60-70% or more occurred throughout the study.
The stimuli for macrophage accumulation in PAGBMN and AcSS remain to be elucidated and are independent of complement components depleted by cobra venom factor (Tables II and V) . In PAGBMN, the occasional PMN present in the glomeruli were insufficient to produce proteinuria but they may still have been adequate to stimulate macrophage localization. Because few macrophages are observed in the heterologous phase of anti-GBM disease where PMN are more prominent, it is unlikely that PMN provide the only stimulus. In AcSS, the dissociation between PMN and macrophages is more complete as glomerular damage has been shown to occur despite PMN depletion (6) .
The role of lymphocyte-directed macrophage involvement in both models is a question that requires further explanation and study. As macrophage localization occurs after 10 (46) .
The glomerular endothelial hypertrophy/hyperplasia evident in both models may result from macrophage-endothelial cell interaction. The ability of macrophages to induce responses of a proliferative, secretory, or immunologic nature in other cells is well established (39, 40) . Potentially most pertinent to glomerular histologic damage is the report that macrophages stimulate endothelial proliferation in delayed hypersensitivity in guinea pigs (47) , and the observation that activated macrophages and macrophageconditioned medium can produce vascular proliferation in the guinea pig cornea (48) . The glomerular endothelial reaction in the current study was greatly diminished by AMS treatment, related to macrophage depletion. Mild residual endothelial changes were evident at the ultrastructural level in both models. The endothelium is presumably responsive to many stimuli and deposition of immune reactants alone may have been sufficient to produce limited injury.
In conclusion, the current study shows that macrophages are associated with histologic damage and proteinuria in glomerulonephritis produced by the two major immune mechanisms of glomerular injury: deposition of circulating immune complexes, in AcSS, and direct antibody binding to the glomerulus, in PAGBMN. The macrophages seen in forms of glomerular injury where other known mediator systems are involved, may contribute in those situations, although their precise role will be difficult to define. This work strongly suggests that macrophages should be included with the PMN among the inflammatory mediators that can induce acute glomerular injury and proteinuria in experimental glomerulonephritis.
